Clinical evaluation of fleroxacin in the treatment of bone and joint infections

Y. C. Liu, D. L. Cheng, C. Y. Liu, S. T. De Garis, H. H. Lin, T. L. Hsieh, M. Y. Yen, R. S. Wang, Y. S. Chen

研究成果: 雜誌貢獻文章

3 引文 (Scopus)

摘要

The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

原文英語
頁(從 - 到)514-519
頁數6
期刊Southeast Asian Journal of Tropical Medicine and Public Health
23
發行號3
出版狀態已發佈 - 1992
對外發佈Yes

指紋

Fleroxacin
Infectious Arthritis
Osteomyelitis
Joints
Bone and Bones
Infection
Therapeutics
Safety
Salmonella enteritidis
Staphylococcus aureus

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Liu, Y. C., Cheng, D. L., Liu, C. Y., De Garis, S. T., Lin, H. H., Hsieh, T. L., ... Chen, Y. S. (1992). Clinical evaluation of fleroxacin in the treatment of bone and joint infections. Southeast Asian Journal of Tropical Medicine and Public Health, 23(3), 514-519.

Clinical evaluation of fleroxacin in the treatment of bone and joint infections. / Liu, Y. C.; Cheng, D. L.; Liu, C. Y.; De Garis, S. T.; Lin, H. H.; Hsieh, T. L.; Yen, M. Y.; Wang, R. S.; Chen, Y. S.

於: Southeast Asian Journal of Tropical Medicine and Public Health, 卷 23, 編號 3, 1992, p. 514-519.

研究成果: 雜誌貢獻文章

Liu, YC, Cheng, DL, Liu, CY, De Garis, ST, Lin, HH, Hsieh, TL, Yen, MY, Wang, RS & Chen, YS 1992, 'Clinical evaluation of fleroxacin in the treatment of bone and joint infections', Southeast Asian Journal of Tropical Medicine and Public Health, 卷 23, 編號 3, 頁 514-519.
Liu, Y. C. ; Cheng, D. L. ; Liu, C. Y. ; De Garis, S. T. ; Lin, H. H. ; Hsieh, T. L. ; Yen, M. Y. ; Wang, R. S. ; Chen, Y. S. / Clinical evaluation of fleroxacin in the treatment of bone and joint infections. 於: Southeast Asian Journal of Tropical Medicine and Public Health. 1992 ; 卷 23, 編號 3. 頁 514-519.
@article{78475e4e147f401aa5414c9193f93205,
title = "Clinical evaluation of fleroxacin in the treatment of bone and joint infections",
abstract = "The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8{\%}) had osteomyelitis and 12 (63.2{\%}) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7{\%}) with osteomyelitis and in 8 of 11 patients (72.11{\%}) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7{\%} and 80.0{\%}, respectively. The clinical response was cure in 4 of 7 patients (57.1{\%}) evaluable for osteomyelitis, and in 9 of 12 patients (75.0{\%}) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.",
author = "Liu, {Y. C.} and Cheng, {D. L.} and Liu, {C. Y.} and {De Garis}, {S. T.} and Lin, {H. H.} and Hsieh, {T. L.} and Yen, {M. Y.} and Wang, {R. S.} and Chen, {Y. S.}",
year = "1992",
language = "English",
volume = "23",
pages = "514--519",
journal = "Southeast Asian Journal of Tropical Medicine and Public Health",
issn = "0125-1562",
publisher = "Southeast Asian Ministers of Education Organisation",
number = "3",

}

TY - JOUR

T1 - Clinical evaluation of fleroxacin in the treatment of bone and joint infections

AU - Liu, Y. C.

AU - Cheng, D. L.

AU - Liu, C. Y.

AU - De Garis, S. T.

AU - Lin, H. H.

AU - Hsieh, T. L.

AU - Yen, M. Y.

AU - Wang, R. S.

AU - Chen, Y. S.

PY - 1992

Y1 - 1992

N2 - The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

AB - The objective of this open label, non-comparative study was to evaluate the efficacy and safety of fleroxacin 400mg administered orally once daily to patients with acute osteomyelitis and/or acute septic arthritis. Nineteen patients (10 males and 9 females) were evaluable for the analysis of clinical efficacy and safety. Of these, 7 (36.8%) had osteomyelitis and 12 (63.2%) had septic arthritis. Bacteriological cures were reported in 6 of 7 patients (85.7%) with osteomyelitis and in 8 of 11 patients (72.11%) with septic arthritis. The median duration of treatment for the clinical cures in osteomyelitis and septic arthritis were 29.5 days and 46 days respectively. The eradication rate for the most common pathogens, Salmonella enteritidis and Staphylococcus aureus were 77.7% and 80.0%, respectively. The clinical response was cure in 4 of 7 patients (57.1%) evaluable for osteomyelitis, and in 9 of 12 patients (75.0%) evaluable for septic arthritis at the three-month follow-up after treatment. Adverse reactions were minimal. It is concluded that fleroxacin appears to be an effective and safe in the treatment of acute osteomyelitis and acute septic arthritis.

UR - http://www.scopus.com/inward/record.url?scp=0027062759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027062759&partnerID=8YFLogxK

M3 - Article

C2 - 1488710

AN - SCOPUS:0027062759

VL - 23

SP - 514

EP - 519

JO - Southeast Asian Journal of Tropical Medicine and Public Health

JF - Southeast Asian Journal of Tropical Medicine and Public Health

SN - 0125-1562

IS - 3

ER -